New developments in BCG vaccine: implications for tuberculosis control.
作者信息
MacIntyre C R
出版信息
Epidemiol Infect. 2007 Feb;135(2):177-80. doi: 10.1017/S0950268806007126.
Abstract
摘要
相似文献
1
New developments in BCG vaccine: implications for tuberculosis control.
Epidemiol Infect. 2007 Feb;135(2):177-80. doi: 10.1017/S0950268806007126.
2
The dream of a vaccine against tuberculosis; new vaccines improving or replacing BCG?
Eur Respir J. 2005 Jul;26(1):162-7. doi: 10.1183/09031936.05.00109904.
3
25th Kellersberger memorial lecture, 2000. The contribution of immunology to tuberculosis control.
Ethiop Med J. 2001 Jan;39(1):75-82.
4
Novel tuberculosis vaccines on the horizon.
Curr Opin Immunol. 2010 Jun;22(3):374-84. doi: 10.1016/j.coi.2010.04.006. Epub 2010 May 12.
5
Tuberculosis control, without protection from BCG.
Indian Pediatr. 2000 Jan;37(1):9-18.
6
Immunoprophylaxis in tuberculosis.
J Commun Dis. 1984 Mar;16(1):49-53.
7
Boosting BCG with MVA85A: the first candidate subunit vaccine for tuberculosis in clinical trials.
Tuberculosis (Edinb). 2005 Jan-Mar;85(1-2):47-52. doi: 10.1016/j.tube.2004.09.015. Epub 2005 Jan 21.
8
Tuberculosis vaccine: time to look into future.
Hum Vaccin Immunother. 2014;10(2):420-2. doi: 10.4161/hv.27108. Epub 2013 Nov 14.
9
Issues facing TB control (8). The future of BCG/vaccine development.
Scott Med J. 2000 Oct;45(5 Suppl):57-8; discussion 59. doi: 10.1177/00369330000450S126.
10
New issues in tuberculosis.
Ann Rheum Dis. 2004 Nov;63 Suppl 2(Suppl 2):ii50-ii56. doi: 10.1136/ard.2004.028258.
引用本文的文献
1
Characterizing the Mycobacterium tuberculosis Rv2707 protein and determining its sequences which specifically bind to two human cell lines.
Protein Sci. 2008 Feb;17(2):342-51. doi: 10.1110/ps.073083308. Epub 2007 Dec 20.
本文引用的文献
1
Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.
Lancet. 2006 Apr 8;367(9517):1173-80. doi: 10.1016/S0140-6736(06)68507-3.
2
Rational vaccine development--a new trend in tuberculosis control.
N Engl J Med. 2005 Oct 13;353(15):1624-5. doi: 10.1056/NEJMcibr053426.
3
Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.
J Clin Invest. 2005 Sep;115(9):2472-9. doi: 10.1172/JCI24617. Epub 2005 Aug 18.
4
The DOTS strategy for controlling the global tuberculosis epidemic.
Clin Chest Med. 2005 Jun;26(2):197-205, v. doi: 10.1016/j.ccm.2005.02.001.
5
A cost-effectiveness analysis of universal versus selective immunization with Mycobacterium bovis bacille Calmette-Guérin in Finland.
Int J Tuberc Lung Dis. 2003 Jan;7(1):22-9.
6
The global tuberculosis situation and the new control strategy of the World Health Organization. 1991.
Bull World Health Organ. 2001;79(1):71-5.
7
Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13853-8. doi: 10.1073/pnas.250480397.
8
An analysis of some hypotheses related to the Chingelput bacille Calmette-Guérin trial.
Clin Infect Dis. 2000 Sep;31 Suppl 3:S77-80. doi: 10.1086/314073.
9
The effect of heterologous immunity upon the apparent efficacy of (e.g. BCG) vaccines.
Vaccine. 1998 Dec;16(20):1923-8. doi: 10.1016/s0264-410x(98)00124-8.
10
A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal.
Vaccine. 1997 Oct;15(15):1606-12. doi: 10.1016/s0264-410x(97)00100-x.
Zotero 插件